Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 104 of 1,261
  1. US 12049487

    Universal chimeric antigen receptor T-cell preparation technique

    GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  2. US 12049479

    Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom

    Inovio Pharmaceuticals, Inc. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  3. US 12049471

    Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof

    NURIX THERAPEUTICS, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  4. US 12048317

    Astaxanthin-containing condiment and a preparation method therefor

    South China University of Technology · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  5. US 12049520

    Bicyclic peptide ligands specific for CD137

    BicycleTx Limited · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  6. US 12048692

    Methods for treating chronic obstructive pulmonary disease

    Theravance Biopharma R&D IP, LLC · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  7. US 12048687

    Methods of recruiting SDF-producing macrophages

    MedRegen, LLC · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  8. US 12048691

    High dosage tebipenem pivoxil tablet formulation

    SPERO THERAPEUTICS, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  9. NZ 743471

    Improved immunoglobulin variable domains

    ABLYNX NV · Granted Jul 26, 2024 · Expires Jul 21, 2044

    granted
  10. CN 118401500

    Process for preparing mixtures of dimeric macrocyclic intermediates comprising gadolinium complexes

    BRACCO IMAGING SPA · Granted Jul 26, 2024 · Expires Jul 21, 2044

    granted
  11. US 12043833

    Targeted compositions

    ARBUTUS BIOPHARMA CORPORATION · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  12. US 12043620

    Benzazole compounds and methods for making and using the compounds

    Rigel Pharmaceuticals, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  13. US 12042541

    Lipids and compositions for the delivery of therapeutics

    ARBUTUS BIOPHARMA CORPORATION · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  14. US 12043607

    HDAC inhibitors and therapeutic use thereof

    Tango Therapeutics, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  15. US 12042538

    Methods of reducing particle formation and compositions formed thereby

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  16. US 12043831

    Modulation of alpha synuclein expression

    Ionis Pharmaceuticals, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  17. US 12043610

    Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  18. US 12042510

    Modulators of IRF4 expression

    Ionis Pharmaceuticals, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  19. US 12043629

    RIP1K inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  20. US 12042487

    Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  21. US 12043640

    Prodrugs of STAT3 inhibitors

    Tvardi Therapeutics, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  22. US 12042529

    Optimization of enzyme replacement therapy for treatment of homocystinuria

    The Regents of the University of Colorado, a Body Corporate · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  23. US 12043655

    Constitutively active chimeric cytokine receptors

    Allogene Therapeutics, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  24. US 12043667

    CLEC12a binding polypeptides and uses thereof

    Inhibrx Biosciences, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.